The Road to Diagnosis: Labs, Imaging, and Guidelines
At a Glance
PBMAH is diagnosed when cortisol stays high after an overnight dexamethasone test, ACTH is often low, and CT shows multiple nodules in both adrenal glands. Doctors also check for other adrenal conditions and assess blood pressure, blood sugar, and bone health.
Diagnosing Primary Bilateral Macronodular Adrenal Hyperplasia (PBMAH) or Bilateral Macronodular Adrenal Disease (BMAD) is a two-part process. Your medical team must first confirm that your adrenal glands are producing cortisol on their own (autonomy) and then use detailed imaging to confirm the presence of multiple large nodules on both glands [1][2].
Current guidelines from the European Society of Endocrinology (ESE) provide a clear roadmap for this process, ensuring that mild cases are caught even if you don’t have obvious physical symptoms [3].
The Diagnostic Cornerstone: The 1-mg DST
The most important test for diagnosing adrenal cortisol issues is the 1-mg overnight dexamethasone suppression test (DST).
- The Procedure: You take a 1-mg tablet of dexamethasone (a synthetic steroid) at 11:00 PM and have your blood drawn for cortisol the following morning between 8:00 AM and 9:00 AM [1].
- The Logic: In a healthy person, the brain senses the dexamethasone and tells the adrenal glands to stop making cortisol. In PBMAH, the adrenal glands ignore this signal and keep pumping out cortisol anyway [1][4].
- The Threshold: According to the 2023 guidelines, if your morning cortisol level is greater than 1.8 µg/dL (50 nmol/L), it suggests Mild Autonomous Cortisol Secretion (MACS) [3][5]. This is a screening threshold, not a standalone diagnosis of PBMAH. The test must be interpreted carefully, as results can be altered by estrogen (like birth control), acute illness, and exposure to exogenous steroids (like joint injections, asthma inhalers, or skin creams) [6][3].
Note: Your doctor may check your dexamethasone levels in the same blood sample to make sure your body processed the pill correctly [6][3].
Confirming Adrenal Independence
Once a high cortisol reading is found, your doctor must prove the problem is in the adrenals and not the brain (pituitary).
- ACTH Levels: This hormone, made by the pituitary, should be very low (suppressed) because the brain is trying to shut down the excess cortisol [1]. While there is no single “magic number,” an ACTH level below 10 pg/mL often points toward the adrenal glands as the source [7].
- DHEAS Levels: DHEAS is another hormone made by the adrenal glands. It is often lower than normal in people with PBMAH because the excess cortisol production suppresses the pathways that make DHEAS [8][9].
What to Look for on Imaging
Imaging (usually a CT scan) is used to see the “macronodules” that give the disease its name.
- Size: By definition, macronodules are larger than 1 cm (0.4 inches) [10][11]. In PBMAH, these nodules are found on both the left and right adrenal glands.
- Appearance: Doctors look at Hounsfield Units (HU), a measure of density on a CT scan.
- Benign (Non-Cancerous): A score of 10 HU or less suggests the nodule is “lipid-rich” (full of fat), which is common in benign adrenal growths [3][10].
- Washout: If a nodule is higher than 10 HU, doctors may use a “washout” study with contrast dye. Most PBMAH nodules show “good washout,” meaning the dye leaves the nodule quickly [10][12].
However, suspicious size, heterogeneity, or growth requires specialist multidisciplinary review rather than relying on HU or washout alone to rule out malignancy or pheochromocytoma.
Ruling Out “Look-Alikes”
Because you have nodules on both sides, your doctor must ensure they aren’t causing other problems. You will likely have blood or urine tests to rule out:
- Pheochromocytoma: A rare tumor that produces adrenaline-like hormones [1][13].
- Primary Aldosteronism: A condition where the glands make too much aldosterone, leading to very high blood pressure and low potassium [14][15].
These tests are selected based on your specific imaging, hypertension, and local guideline criteria; not every patient needs every test.
Completeness Checklist
To ensure an accurate diagnosis, your medical report should ideally include the following information. You can use this list to review your results with your doctor:
- [ ] Hormone Results: Cortisol level after 1-mg DST (is it >1.8 µg/dL?).
- [ ] ACTH Level: Is it low or suppressed?
- [ ] DHEAS Level: Is it below the normal range for your age?
- [ ] Nodule Details: Number, side (left, right, or both), and size (in cm) of all nodules.
- [ ] Density (HU): Are the nodules 10 HU or less?
- [ ] Other Adrenal Tests: Results for metanephrines (to rule out pheochromocytoma) and aldosterone-renin ratio (to rule out primary aldosteronism), if indicated.
- [ ] Comorbidity Check: Documentation of your blood pressure, blood sugar (A1c), and bone density [3].
Common questions in this guide
What test is usually used first to check for cortisol production in PBMAH?
What does a low ACTH level mean in suspected PBMAH?
How can a CT scan help diagnose bilateral macronodular adrenal disease?
Can medications or illness affect the dexamethasone suppression test?
Will I need tests for pheochromocytoma or primary aldosteronism?
What does mild autonomous cortisol secretion mean?
One line in your results can change your plan.
An ACTH level can help show whether the adrenal glands, rather than the pituitary, are the source of high cortisol. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on Cushing syndrome due to bilateral macronodular adrenocortical disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Diagnosis and management of primary bilateral macronodular adrenal hyperplasia
Vassiliadi DA, Tsagarakis S
Endocrine-related cancer 2019; (26(10)):R567-R581.
PMID: 32053747 - 2
Clinical, Pathophysiologic, Genetic, and Therapeutic Progress in Primary Bilateral Macronodular Adrenal Hyperplasia.
Bertherat J, Bourdeau I, Bouys L, et al.
Endocrine reviews 2023; (44(4)):567-628 doi:10.1210/endrev/bnac034.
PMID: 36548967 - 3
European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M, Tsagarakis S, Terzolo M, et al.
European journal of endocrinology 2023; (189(1)):G1-G42 doi:10.1093/ejendo/lvad066.
PMID: 37318239 - 4
Mild autonomous cortisol secretion: Diagnosis.
Pinto L, Donato S
Vitamins and hormones 2026; (132()):243-272 doi:10.1016/bs.vh.2026.02.005.
PMID: 42236010 - 5
Recent Updates on the Management of Adrenal Incidentalomas.
Park SS, Kim JH
Endocrinology and metabolism (Seoul, Korea) 2023; (38(4)):373-380 doi:10.3803/EnM.2023.1779.
PMID: 37583083 - 6
Value of the Serum Dexamethasone Determination for the Diagnosis of Mild Autonomous Cortisol Secretion.
Araujo-Castro M, Cortés Gómez A, Rosillo M, et al.
Clinical endocrinology 2026; (104(5)):428-435 doi:10.1111/cen.70065.
PMID: 41298283 - 7
ACTH following overnight dexamethasone suppression can be used in the verification of autonomous cortisol secretion in patients with adrenal incidentalomas.
Puvaneswaralingam S, Kjellbom A, Lindgren O, et al.
Clinical endocrinology 2021; (94(2)):168-175 doi:10.1111/cen.14357.
PMID: 33108675 - 8
Performance of DHEAS as a Screening Test for Autonomous Cortisol Secretion in Adrenal Incidentalomas: A Prospective Study.
Liu MS, Lou Y, Chen H, et al.
The Journal of clinical endocrinology and metabolism 2022; (107(5)):e1789-e1796 doi:10.1210/clinem/dgac072.
PMID: 35137142 - 9
[The value of dehydroepiandrosterone sulfate in the differential diagnosis of primary bilateral adrenal macronodular hyperplasia].
Rao XJ, Jiang DY, Zang L, et al.
Zhonghua yi xue za zhi 2024; (104(30)):2830-2836 doi:10.3760/cma.j.cn112137-20240201-00248.
PMID: 39085151 - 10
Bilateral macronodular adrenocortical disease: a single centre experience.
Ban A, Barnabas R, Karlekar M, et al.
Endocrine connections 2025; (14(3)).
PMID: 39887684 - 11
Clinical heterogeneity and imaging-driven genetic screening priorities in patients with radiologically suspected primary bilateral macronodular adrenal hyperplasia.
Xu H, Li B, Chen K, et al.
Endocrine connections 2025; (14(10)).
PMID: 41042544 - 12
Evaluation of adrenal incidentalomas: Current approaches, caveats, and unexplored issues.
Kouroglou E, Tsiama V, Stroumpouli E, et al.
World journal of radiology 2026; (18(4)):119833 doi:10.4329/wjr.v18.i4.119833.
PMID: 42057842 - 13
MANAGEMENT OF ENDOCRINE DISEASE: Differential diagnosis, investigation and therapy of bilateral adrenal incidentalomas.
Bourdeau I, El Ghorayeb N, Gagnon N, Lacroix A
European journal of endocrinology 2018; (179(2)):R57-R67.
PMID: 29748231 - 14
Prevalence and main characteristics of primary aldosteronism in bilateral macronodular adrenal disease: a systematic review of the literature.
Panarelli A, Schweizer JROL, Stüfchen I, et al.
European journal of endocrinology 2025; (192(3)):S15-S25 doi:10.1093/ejendo/lvaf020.
PMID: 39965111 - 15
ARMC5 Mutations in a Large Cohort of Primary Macronodular Adrenal Hyperplasia: Clinical and Functional Consequences.
Espiard S, Drougat L, Libé R, et al.
The Journal of clinical endocrinology and metabolism 2015; (100(6)):E926-35 doi:10.1210/jc.2014-4204.
PMID: 25853793
This page is for informational purposes only and does not constitute medical advice about PBMAH. Your endocrinology team should interpret your hormone results, medication history, and CT findings in context.